Governance Neutral

2026-11-04 15:16

- Cipla Ltd has announced the appointment of Mr Vikram Janakiraman as the Global Chief Technical Operating Officer and Senior Management Personnel, effective 7th December, 2026. - Mr Janakiraman brings around 30 years of experience, previously serving as Managing Director and Senior Partner at Boston Consulting Group (BCG) and holding leadership roles at Glenmark Pharmaceuticals.

Governance Neutral

2026-11-04 15:11

- Cipla Limited has informed the exchange about the appointment of Mr. Vikram Janakiraman as the Global Chief Technical Operating Officer and Senior Management Personnel, effective 7th December, 2026. - He brings approximately 30 years of experience, previously serving as Managing Director and Senior Partner at Boston Consulting Group (BCG) and in leadership roles at Glenmark Pharmaceuticals.

Business Update Positive

2026-10-30 17:33

Management highlighted robust Q2 FY27 performance with revenue of INR 7,404 crores and sequential EBITDA margin expansion of 200 bps to 18.7%. - Reaffirmed guidance of reaching $1 billion annualized revenue run-rate in the U.S. by the end of FY27 and full-year EBITDA margin of 18.5% to 20%. - Key approvals secured include generic Advair in the U.S. and an exclusive partnership with Qilu for Pembrolizumab biosimilar commercialization in North America. - One India business delivered 12% YoY growth, driven by strong performance across chronic therapies including respiratory, anti-diabetes, and dermatology.

Business Update Positive

2026-10-30 17:25

Current scenario: Q2 FY27 revenue reported at INR7,404 crores with a sequential growth of 4% Q-o-Q, driven by broad-based performance across key businesses. EBITDA margin excluding other income stood at 18.7%, reflecting a 200 bps sequential improvement. Profit after tax stood at INR878 crores. Management Guidance & Outlook: Management remains confident of achieving the U.S. exit run rate of $1 billion for the fiscal year, supported by product launches like generic Ventolin and Advair, alongside three additional expected significant launches including two respiratory assets and one peptide opportunity. Full-year EBITDA margin guidance maintained at 18.5% to 20%. Growth Drivers: One India delivered 12% Y-o-Y growth led by chronic therapies and new product introductions. North America revenue improved to $172 million, up $10 million Q-o-Q. Strategic partnerships like the exclusive licensing agreement with CTTQ for a novel HER2 bispecific ADC and Qilu Pharmaceutical for Pembrolizumab biosimilar strengthen the innovative oncology and biosimilar pipelines.

Routine Neutral

2026-10-29 20:39

- Cipla Limited has allotted 17,453 fully paid-up equity shares of INR 2 each on 29th October, 2026. - Allotment is pursuant to the exercise of employee stock options/stock appreciation rights under ESOS 2013-A and Cipla ESAR Scheme 2021. - Post-allotment, the paid-up share capital increases to INR 1,61,57,76,136 comprising 80,78,88,068 equity shares.

Governance Neutral

2026-10-29 20:37

- Cipla Ltd announced the allotment of 17,453 fully paid-up equity shares of INR 2 each on 29th October, 2026. - Shares were allotted pursuant to the exercise of options under ESOS 2013-A and Cipla ESAR Scheme 2021. - Post-allotment, the paid-up share capital increased to INR 1,61,57,76,136 comprising 80,78,88,068 equity shares.

Business Update Neutral

2026-10-27 18:54

- Cipla Ltd. informed about the availability of the audio recording of the earnings conference call for the quarter and half year ended 30th September, 2026. - The audio recording is accessible on the company's website.

Routine Neutral

2026-10-27 18:49

- Cipla Limited informed the exchanges about the audio recording of the earnings conference call for the quarter and half year ended 30th September, 2026. - The audio recording is made available on the company's website.

Governance Neutral

2026-10-27 13:56

- Cipla Ltd has granted 8,679 stock options under ESOS 2013-A with a vesting period of 2 years and exercise price of INR 2 per option. - The company has also granted 27,140 Employee Stock Appreciation Rights (ESARs) under ESAR 2021 with a 3-year graded vesting and exercise price of INR 2 per share.

Governance Neutral

2026-10-27 13:53

- Appointed Ms Rashmi Joshi as an additional and independent director for a 5-year term starting 27th October, 2026. - Ms Rashmi Joshi is a qualified Chartered Accountant and Company Secretary with over three decades of experience across multinational organizations.

Governance Neutral

2026-10-27 13:50

- Appointment of Ms Rashmi Joshi as an Additional and Independent Director for a 5-year term effective from 27th October, 2026, subject to shareholder approval. - Ms Rashmi Joshi is a qualified Chartered Accountant and Company Secretary with over 30 years of global corporate experience across FMCG, pharmaceuticals, and other sectors.

Governance Neutral

2026-10-27 13:49

- Cipla Limited has announced the grant of 8,679 stock options under ESOS 2013-A with a vesting period of 2 years and an exercise price of INR 2 per option. - The company also granted 27,140 Employee Stock Appreciation Rights (ESARs) under ESAR 2021 with a 3-year graded vesting and an exercise price of INR 2 per equity share.

Governance Neutral

2026-10-27 13:46

- Cipla Limited has announced the appointment of Ms. Rashmi Joshi as an additional and independent director for a term of 5 years effective October 27, 2026. - The appointment is subject to the approval of shareholders. - Ms. Rashmi Joshi is a qualified Chartered Accountant and Company Secretary with over three decades of corporate experience.

Governance Neutral

2026-10-27 13:43

- Appointed Ms Rashmi Joshi as an Additional and Independent Director of the company for a term of 5 years effective October 27, 2026. - The appointment is subject to the approval of shareholders. - Ms Joshi is a qualified Chartered Accountant and Company Secretary with over three decades of experience.

Business Update Neutral

2026-10-27 13:42

- Cipla reported Q2FY27 Consolidated Revenue of ₹7,404 Cr (vs ₹7,589 Cr YoY) with an EBITDA margin of 18.7%. - Net Profit (PAT) stood at ₹878 Cr compared to ₹1,351 Cr in Q2FY26. - One India recorded its highest-ever quarterly revenue at ₹3,516 Cr. - Entered strategic partnerships for oncology biosimilars and ADCs.

Business Update Neutral

2026-10-27 13:41

- Q2FY27 consolidated revenue reached ₹7,404 Cr vs ₹7,589 Cr YoY - EBITDA stood at ₹1,388 Cr (18.7% margin) vs ₹1,895 Cr YoY - Net profit (PAT) was ₹878 Cr vs ₹1,351 Cr YoY - One India business delivered highest-ever quarterly revenue of ₹3,516 Cr - Formed strategic licensing partnerships for Keytruda biosimilar and HER2 ADC

Financials Neutral

2026-10-27 13:37

Q2 FY27 Consolidated Revenue ₹7,404Cr vs ₹7,589Cr (▼2% YoY) EBITDA ₹1,388Cr vs ₹1,895Cr (▼27% YoY) PAT ₹878Cr vs ₹1,351Cr (▼35% YoY) EBITDA Margin 18.7% vs 25.0% (▼630bps)

Financials Neutral

2026-10-27 13:36

Q2 FY27 Consolidated Revenue ₹7,404 Cr vs ₹7,589 Cr (▼2% YoY) EBITDA ₹1,388 Cr vs ₹1,895 Cr (▼27% YoY) PAT ₹878 Cr vs ₹1,351 Cr (▼35% YoY) EBITDA Margin 18.7% vs 25.0% (▼630bps)

Financials Neutral

2026-10-27 13:33

Q2 FY27 Consolidated Revenue ₹7,403.93Cr vs ₹7,589.44Cr (▼2.4% YoY) EBITDA ₹1,387.78Cr vs ₹1,894.75Cr (▼26.8% YoY) PAT ₹851.51Cr vs ₹1,353.37Cr (▼37.1% YoY) EBITDA Margin 18.7% vs 25.0% (▼623bps)

Financials Neutral

2026-10-27 13:24

Q2 FY27 Consolidated Revenue ₹7,403.93Cr vs ₹7,589.44Cr (▼2.4% YoY) EBITDA ₹1,387.78Cr vs ₹1,894.75Cr (▼26.8% YoY) PAT ₹851.51Cr vs ₹1,353.37Cr (▼37.1% YoY) EBITDA Margin 18.74% vs 24.97% (▼623bps)

Business Update Positive

2026-10-23 09:04

- USFDA conducted a routine cGMP inspection at the InvaGen Pharmaceuticals manufacturing facility in New York, USA, from 19th October to 22nd October 2026. - The inspection successfully concluded with zero Form 483 observations.

Business Update Positive

2026-10-23 09:03

- Cipla informed that the USFDA conducted a routine cGMP inspection at its wholly owned subsidiary InvaGen Pharmaceuticals Inc.'s facility in Hauppauge, New York, USA. - The inspection took place from 19th October, 2026 to 22nd October, 2026. - The inspection successfully concluded with zero Form 483 observations.

Business Update Neutral

2026-10-13 18:59

Concall Schedule Concall Date: 27th October 2026 Concall Time: 1600 hrs IST

Business Update Neutral

2026-10-13 18:58

Concall Schedule Concall Date: 27th October 2026 Concall Time: 1600 hrs IST

Governance Neutral

2026-09-28 19:21

- Board meeting scheduled on Tuesday, 27th October, 2026 to approve Q2 FY27 unaudited financial results. - Trading window to remain closed from 1st October, 2026 till 29th October, 2026.

Routine Neutral

2026-09-24 19:08

- Cipla Ltd. has allotted 12,168 equity shares of face value INR 2 each on 24th September 2026 under ESOS 2013-A and Cipla ESAR Scheme 2021. - The total paid-up share capital of the company increased to INR 1,61,57,41,230 comprising 80,78,70,615 equity shares.

Routine Neutral

2026-09-24 19:04

- Cipla Limited has allotted 12,168 equity shares of face value INR 2 each on 24th September 2026. - Allotment done pursuant to the exercise of options under ESOS 2013-A and Cipla ESAR Scheme 2021. - Paid-up share capital increased to INR 1,61,57,41,230 comprising 80,78,70,615 equity shares.

Governance Neutral

2026-09-22 22:58

- Mr Venkata Sai Mungara, Global Head Supply Chain, transitioned to Chief of Manufacturing and Supply Chain Operations of Cipla USA Inc. (wholly owned subsidiary). - He will cease to be a Senior Management Personnel of Cipla Limited effective from October 1, 2026.

Governance Neutral

2026-09-22 22:57

- Mr. Venkata Sai Mungara transitioned to Chief of Manufacturing & Supply Chain Operations, Cipla USA Inc. - He will cease to be a Senior Management Personnel of Cipla Limited from October 1, 2026.

Business Update Positive

2026-09-18 17:34

- Cipla received an ESG rating of 68 from Niche, a SEBI registered ESG Rating Provider. - The company was notified by BSE/NSE alerts on Sept 11/17, 2026.

Business Update Positive

2026-09-18 17:33

- Cipla has been assigned an Environmental, Social, and Governance (ESG) rating of 68 by Niche, a SEBI registered ESG Rating Provider. - The company became aware of the rating via an alert disseminated by BSE on September 17, 2026.

Business Update Positive

2026-09-03 20:18

- Cipla announced an exclusive partnership with Qilu Pharmaceutical for the licensing and supply of QL2107, a biosimilar to Keytruda® (Pembrolizumab), in the US. The collaboration aims to expand Cipla's oncology portfolio and enhance access to affordable biologic therapies.

Business Update Positive

2026-09-03 20:17

- Cipla announced an exclusive partnership with Qilu Pharmaceutical for the licensing and supply of QL2107, a biosimilar to Keytruda® (Pembrolizumab), in the US market. - Qilu will handle development, regulatory registration, and supply, while Cipla USA Inc. will be responsible for commercialization.

Business Update Neutral

2026-09-03 16:52

- Cipla intimates shareholders and creditors about the NCLT-approved Scheme of Amalgamation of Inzpera Healthsciences Ltd. with Cipla Ltd. by an order dated 18th August 2026. - Shareholders/creditors have 30 days from notice receipt to submit representations to NCLT regarding the scheme.

Business Update Positive

2026-09-03 16:45

- Cipla informed about the Scheme of Amalgamation (by Absorption) of Inzpera Healthsciences Limited with Cipla Limited, as per NCLT order dated August 18, 2026. - The NCLT has dispensed with meetings of the equity shareholders and unsecured creditors of Cipla. - Shareholders and creditors can submit representations regarding the proposed Scheme to the NCLT within 30 days.

Business Update Positive

2026-08-31 15:56

- Cipla and SBP Group signed an exclusive licensing agreement for Rolditamig Deuderuxtecan (TQB2102), a potential best-in-class HER2 bispecific ADC. - Cipla gains exclusive rights to develop and commercialize the drug in India, South Africa, and 5 other emerging markets.

Business Update Positive

2026-08-31 15:45

- Cipla Limited and SBP Group signed an exclusive licensing agreement for Rolditamig Deuderuxtecan (TQB2102), a potential best-in-class HER2 bispecific ADC. Cipla gains exclusive rights for development and commercialisation in India, South Africa, and 5 other emerging markets.

Business Update Positive

2026-08-28 21:18

- USFDA inspection at Cipla's subsidiary InvaGen's manufacturing facility in Central Islip, NY, USA, from July 13-17, 2026, has been classified as 'Voluntary Action Indicated (VAI)'.

Business Update Positive

2026-08-28 21:12

- USFDA inspection at Cipla's subsidiary, InvaGen Pharmaceuticals Inc.'s Central Islip manufacturing facility (July 13-17, 2026), has been classified as 'Voluntary Action Indicated' (VAI) by the USFDA via communication dated August 28, 2026.

Business Update Neutral

2026-08-27 20:22

- Cipla's JV, Aspergen Limited (India), acquired 100% stake in Aspergen Inc. (USA) from Cipla (EU) Limited and Kemwell Biopharma UK Limited. - This restructuring rationalises and simplifies the group structure. - There is no change in Cipla's economic interest in Aspergen Inc. (USA).

Business Update Neutral

2026-08-27 20:17

- Cipla announced a group restructuring to rationalize and simplify its structure. - Aspergen Limited, India (a JV), acquired 100% stake in Aspergen Inc., USA, a step-down subsidiary. - Cipla's economic interest in Aspergen Inc., USA, remains unchanged post-restructuring.

Business Update Neutral

2026-08-27 14:56

- Cipla Ltd. intimated the schedule of Analyst / Institutional Investor Meetings. - 17th September 2026: Jefferies India Forum Conference in Gurgaon (In person). - 18th September 2026: Kotak Healthcare Conference in Mumbai (In person).

Business Update Neutral

2026-08-27 14:50

- Cipla has scheduled meetings with analysts/institutional investors. - September 17, 2026: Jefferies India Forum Conference in Gurgaon (In person). - September 18, 2026: Kotak Healthcare Conference in Mumbai (In person).

Ownership Neutral

2026-08-26 17:46

- Cipla Ltd. allotted 5,281 fully paid-up equity shares of INR 2 each on August 26, 2026. - This allotment was made under the ESOS 2013-A Scheme and Cipla ESAR Scheme 2021. - Consequently, the company's paid-up share capital increased to INR 1,61,57,16,894, comprising 80,78,58,447 equity shares.

Ownership Neutral

2026-08-26 17:37

- On August 26, 2026, Cipla Limited allotted 5,281 fully paid-up equity shares of INR 2 each under its ESOS 2013-A and ESAR 2021 schemes. - Post-allotment, the company's paid-up share capital increased to INR 1,61,57,16,894, comprising 80,78,58,447 equity shares.

Business Update Negative

2026-08-25 16:13

CRITICAL RED FLAG DETECTED

- USFDA conducted a cGMP inspection at Cipla's Pithampur manufacturing facility from August 17-25, 2026. - The inspection concluded with seven (7) observations in Form 483. - Cipla is committed to addressing these observations comprehensively.

Business Update Negative

2026-08-25 16:05

CRITICAL RED FLAG DETECTED

- USFDA conducted a cGMP inspection at Cipla's Pithampur manufacturing facility from August 17-25, 2026. - The company received seven (7) inspectional observations in Form 483. - Cipla is committed to addressing these observations comprehensively.

Business Update Positive

2026-08-19 17:05

- Cipla Limited received NCLT approval on August 18, 2026, for the amalgamation of its wholly-owned subsidiary, Inzpera Healthsciences Limited, into Cipla. - The scheme, effective April 1, 2026, aims for operational efficiency, cost savings, and enhanced shareholder value, with no adverse impact on creditors.

Business Update Positive

2026-08-19 17:03

- NCLT approved the Scheme of Amalgamation of Inzpera Healthsciences Limited (wholly-owned subsidiary) with Cipla Limited, effective August 18, 2026. - The amalgamation seeks operational consolidation, efficiency, and cost savings, without adversely affecting creditors or shareholders.

Business Update Negative

2026-08-11 13:27

CRITICAL RED FLAG DETECTED

- Cipla announced ESG ratings for FY25-26. - SES rating rose slightly to 69.9 (Grade B). - NSE rating declined to 67 (Aspiring) from 69 due to a product recall by Cipla USA Inc. in January 2026.

Business Update Negative

2026-08-11 13:26

CRITICAL RED FLAG DETECTED

- Cipla received updated ESG ratings from SES and NSE. - SES ESG rating for FY26 improved to 69.9 (Grade B) from 69.3 (Grade B) in FY25. - NSE ESG rating for FY26 declined to 67 (Aspiring) from 69 (Aspiring) in FY25, potentially due to a product recall by Cipla USA Inc. in January 2026.

Business Update Positive

2026-08-04 08:59

- Cipla's wholly-owned subsidiary, InvaGen Pharmaceuticals, Inc., has received an Establishment Inspection Report (EIR) from the USFDA. - This indicates the closure of the Pre-Approval Inspection (PAI) at its Hauppauge, Long Island, New York, USA manufacturing facility.

Business Update Positive

2026-08-04 08:58

- Cipla's wholly-owned subsidiary, InvaGen Pharmaceuticals, Inc., received an Establishment Inspection Report (EIR) from the USFDA, signifying the closure of the Pre-Approval Inspection at its Hauppauge, New York facility.

Routine Neutral

2026-07-31 22:22

- Cipla Limited allotted 7,850 fully paid-up equity shares of INR 2 each on July 31, 2026, under its ESOS 2013-A Scheme and ESAR Scheme 2021. - This allotment increased the total paid-up share capital to INR 1,61,57,06,332 (80,78,53,166 equity shares).

Routine Neutral

2026-07-31 22:20

- Cipla Limited allotted 7,850 equity shares of INR 2 each on July 31, 2026, under its ESOS 2013-A and ESAR 2021 schemes. - This allotment increases the company's issued, subscribed, and paid-up share capital to INR 1,61,57,06,332 (80,78,53,166 equity shares).

Business Update Positive

2026-07-27 22:57

- Cipla received U.S. FDA approval for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) in all three strengths. - The product is expected to be launched in Q2 of FY 2026-27 in the United States of America. - The U.S. market for this product is approximately $908 million.

Business Update Positive

2026-07-27 22:55

- Cipla received U.S. FDA approval for its Generic Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) in all three strengths. - The U.S. market for this product is approximately $908 million. - The product is expected to be launched in Q2 of FY 2026-27 in the United States.

Business Update Positive

2026-07-27 17:16

- The company reported Q1 FY27 revenue of INR 7,119 crores (2% YoY growth, 4% adjusted for accounting change) and PAT of INR 789 crores. Consolidated EBITDA margin for the quarter was 16.7%.

Business Update Positive

2026-07-27 17:13

- Company reiterates FY27 EBITDA margin guidance of 18.5% to 20%, expecting gradual improvement in coming quarters, despite some current gross margin impacts from product mix, inventory write-offs, and war-related costs. - Reaffirms target of $1 billion U.S. segment exit run rate for FY27, to be driven by new product launches including generic Ventolin, three respiratory assets (e.g., generic Advair), and a peptide product. - North America business expects sequential growth, while One India aims to sustain growth momentum across branded generic, trade generic, and consumer wellness, having achieved its highest ever Q1 revenue of INR 7,100 crores. - Capital allocation priorities include increased Capex for organic growth, R&D, biosimilars, and looking for differentiated portfolio acquisitions/in-licensing. - U.S. FDA GMP inspection at Verna, Goa facility was classified as VAI. One Form 483 observation at Invagen facility is being addressed and is not expected to delay major respiratory launches. - Net cash equivalent balance stood at INR 9,494 crores as of June 30, 2026, with debt at INR 600 crores.

Business Update Neutral

2026-07-23 19:30

- Audio recording of the earnings conference call for the quarter ended 30th June, 2026, is available on the Company's website. - The recording can be accessed at https://www.cipla.com/audio/15001.

Business Update Neutral

2026-07-23 19:27

- Audio recording of the earnings conference call for the quarter ended 30th June, 2026 is available on the Company's website at https://www.cipla.com/audio/15001.

Governance Neutral

2026-07-23 16:21

- Board approved changes in Key Managerial Personnel (KMPs) and Officers authorized under Regulation 30(5), effective July 24, 2026. - The filing provides contact details for these authorized KMPs/Officers.

Governance Neutral

2026-07-23 13:33

- Board of Directors approved changes in Key Managerial Personnel (KMPs) and officers authorized under Regulation 30(5) of SEBI Listing Regulations, effective July 24, 2026. The filing lists the contact details of the authorized KMPs.

Business Update Positive

2026-07-23 13:26

- Cipla Limited granted 5,530 stock options (ESOS 2013-A) and 19,179 Employee Stock Appreciation Rights (ESARs 2021).- Exercise price for both is INR 2 per option/share.- Vesting periods are 2 or 3 years; exercise period is 5 years from vesting.

Business Update Positive

2026-07-23 13:25

- Cipla Ltd. granted 5,530 stock options under ESOS 2013-A and 19,179 Employee Stock Appreciation Rights (ESARs) under ESAR 2021. - Stock options vest in 2 years, while ESARs have 3-year graded vesting. - Both have a 5-year exercise period from vesting date, with an exercise price of INR 2 per option/share.

Governance Neutral

2026-07-23 13:23

- Board of Directors approved a change in reporting for Mr. Sanjay Joseph, Head – API Business. - He will cease to be a Senior Managerial Personnel (SMP) with effect from July 24, 2026.

Governance Neutral

2026-07-23 13:19

- Mr. Sanjay Joseph, Head – API Business, will cease to be a Senior Managerial Personnel (SMP) of Cipla Limited. - This change is effective from July 24, 2026, due to a change in his reporting structure.

Governance Neutral

2026-07-23 13:18

- Mr. Ashish Adukia transitioned from Global Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) to an internal business leadership role, effective July 23, 2026. - Mr. Dinesh Jain was appointed as Global CFO and KMP, effective July 24, 2026. Mr. Jain previously served as Head – Corporate Finance at Cipla.

Governance Neutral

2026-07-23 13:16

- Mr. Ashish Adukia transitioned from Global Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) to an internal business leadership role, effective July 23, 2026. - Mr. Dinesh Jain, currently Head – Corporate Finance at Cipla, has been appointed as the new Global CFO and KMP, effective July 24, 2026.

Governance Neutral

2026-07-23 13:15

- Mr. Ashish Adukia transitioned from Global CFO and KMP to an internal business leadership role, effective July 23, 2026. - Mr. Dinesh Jain, Head – Corporate Finance, has been appointed as the new Global CFO and KMP, effective July 24, 2026. Mr. Jain is a seasoned finance leader with over three decades of experience.

Financials Negative

2026-07-23 12:45

- Consolidated Revenue ₹7,119 Cr vs ₹6,957 Cr (▲2% YoY) - EBITDA ₹1,192 Cr vs ₹1,778 Cr (▼33% YoY) - PAT ₹789 Cr vs ₹1,298 Cr (▼39% YoY) - EBITDA Margin 16.7% vs 25.6% (▼890bps) - One-India business recorded highest quarterly sales with 12% YoY growth. - North America delivered $162 Mn revenue; expect continued sequential growth with upcoming product pipeline.

Financials Negative

2026-07-23 12:41

- Consolidated Revenue ₹7,119 Cr vs ₹6,957 Cr (▲2% YoY) - EBITDA ₹1,192 Cr vs ₹1,778 Cr (▼33% YoY) - PAT ₹789 Cr vs ₹1,298 Cr (▼39% YoY) - EBITDA Margin 16.7% vs 25.6% (▼890bps)

Financials Negative

2026-07-23 12:02

- Consolidated Revenue ₹7,119.28 Cr vs ₹6,957.47 Cr (▲2.33% YoY) - EBITDA ₹1,192.3 Cr vs ₹1,778.14 Cr (▼32.95% YoY) - PAT ₹789.05 Cr vs ₹1,297.62 Cr (▼39.19% YoY) - EBITDA Margin 16.75% vs 25.56% (▼881 bps)

Financials Negative

2026-07-23 11:58

CRITICAL RED FLAG DETECTED

- Consolidated Revenue ₹7,119Cr vs ₹6,957Cr (▲2.3% YoY) - EBITDA ₹1,192Cr vs ₹1,778Cr (▼33.0% YoY) - PAT ₹789Cr vs ₹1,298Cr (▼39.2% YoY) - EBITDA Margin 16.8% vs 25.6% (▼880bps)

Business Update Negative

2026-07-18 09:32

CRITICAL RED FLAG DETECTED

- USFDA conducted a routine cGMP inspection at Cipla's subsidiary InvaGen's manufacturing facility in Central Islip, NY, from July 13-17, 2026. - The company received 1 (one) inspectional observation in Form 483 upon conclusion of the inspection. - Cipla is committed to addressing the observation with the USFDA.

Business Update Positive

2026-07-12 11:31

- Cipla received ESG ratings from Crisil ESG Ratings & Analytics Limited. The company has been assigned 'Crisil ESG 69' and 'Crisil Core ESG 66' ratings.

Business Update Neutral

2026-07-08 13:38

- Concall Schedule - Concall Date: July 23, 2026 - Concall Time: 1600 hrs IST

Business Update Positive

2026-07-04 19:00

CRITICAL RED FLAG DETECTED

- Management highlighted Cipla's strong performance with highest ever yearly revenue over ₹28,000 crores and healthy EBITDA (21%) and PAT (13.8%) margins for the last financial year. - Outlook for FY27 includes 12-15 USFDA filings and 40-50 filings over the next three years, with growth driven by new, complex products in respiratory, peptides, and biosimilars. - Strategic focus on leadership in India (respiratory, chronic diseases), differentiated products in North America, and strengthening presence in Europe and Emerging Markets. - R&D expenditure at ~7% of revenue, investing in future pipeline; cash position increased to ₹11,000 crores. - Addressing regulatory matters: Goa facility received VAI, Indore remediations completed and awaiting USFDA re-audit; working to restore Lanreotide supplies halted due to partner's USFDA observations. - Continued commitment to ESG, aiming for net-zero by 2050, and improving gender diversity in the workforce.

Business Update Positive

2026-07-03 18:47

- Reported highest ever yearly revenue of over ₹28,000 crores for FY26. - Achieved 21% EBITDA margin and 13.8% PAT margin in FY26. - India business grew 9% YoY to cross ₹12,500 crores; North America revenue was $780 million, and One Africa revenue was $483 million (7% growth). - Cash position increased from ₹5,000 crores to ₹11,000 crores in FY26, with approximately 7% of revenue (₹1,974 crores) invested in R&D. - Declared a final dividend of ₹30 per equity share for FY26. - Outlook includes 12-15 USFDA filings in FY27 (40-50 over 3 years) with a focus on complex, high-margin products to drive future growth. - Proactively addressing USFDA observations for a partner's Greece facility (Lanreotide supply) and awaiting re-audit for the Indore facility (remediations completed). - Committed to sustainability with a net-zero target by 2050, achieved 2.6 times water positivity, and utilizes 84% renewable electricity.

Governance Neutral

2026-06-25 22:02

- At the 90th Annual General Meeting held on June 25, 2026, members approved the appointment of M/s B S R & Co. LLP as Statutory Auditors for a term of five years, effective from the conclusion of the 90th AGM till the 95th AGM. - M/s Walker Chandiok & Co. LLP completed their second term and ceased to be the Statutory Auditors of the Company.

Governance Positive

2026-06-25 21:56

- The 90th Annual General Meeting was held on June 25, 2026, via video conferencing. - Proceedings included speeches by the Chairman and MD & GCEO, highlighting 90 years of operations. - Mr. Achin Gupta was welcomed as MD & Global CEO.

Governance Positive

2026-06-25 21:37

- The 90th Annual General Meeting (AGM) of Cipla Limited was held on June 25, 2026. - All resolutions proposed at the AGM, including the declaration of dividend on equity shares, were passed.

Business Update Negative

2026-06-25 15:05

- Cipla's ESG rating has been revised from 68 to 64 by ESGRisks.ai. - The revision is based on re-evaluation of publicly available and new information.

Governance Positive

2026-06-16 13:19

- The Board approved the appointment of Mr. Shivam Puri as CEO – One India Business and Senior Management Personnel, effective from July 1, 2026. - The Board also approved the grant of 11,360 stock options and 51,394 Employee Stock Appreciation Rights (ESARs) under existing schemes.

Governance Positive

2026-06-16 13:11

- Board approved the appointment of Mr. Shivam Puri as CEO – One India Business and Senior Management Personnel, effective July 1, 2026. - Also approved the grant of 11,360 Stock Options and 51,394 Employee Stock Appreciation Rights (ESARs) under existing schemes.

Business Update Positive

2026-06-11 14:06

- USFDA inspection at Cipla's Verna, Goa manufacturing facility from April 6-17, 2026. - The inspection has been classified as 'Voluntary Action Indicated (VAI)' by the USFDA on June 10, 2026.

Routine Neutral

2026-06-09 19:38

New Filing detected. See link for details.

Financials Positive

2026-06-08 22:06

- The Board of Directors has recommended a final dividend of ₹13/- per equity share for FY 2025-26, to be declared at the 90th Annual General Meeting. - Shareholders can submit requisite documents by Monday, June 15, 2026, to avail a nil or lower rate of tax deduction at source on this dividend.

Ownership Neutral

2026-06-04 19:37

- Cipla Limited allotted 44,770 fully paid-up equity shares (face value INR 2 each) on June 4, 2026. - This allotment is pursuant to the exercise of employee stock options/stock appreciation rights under the ESOS 2013-A and ESAR 2021 schemes. - The company's issued, subscribed, and paid-up share capital has increased to INR 1,61,56,90,632, comprising 80,78,45,316 equity shares.

Business Update Neutral

2026-06-02 17:01

- Investor Meeting Schedule - Meeting Date: 9th June 2026 - Investor: ICICI Securities India Investor Conference - Venue: Mumbai - Type of Meeting: In person

Business Update Neutral

2026-06-01 23:40

- Cipla Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. - The report provides details on the company's ESG performance, policies, and governance practices. - It highlights manufacturing (69.03%) and trade (21.06%) as main activities. - Achin Gupta was appointed MD & GCEO effective April 1, 2026, replacing Umang Vohra.

Governance Positive

2026-06-01 23:29

- Cipla Limited's 90th Annual General Meeting (AGM) will be held on Thursday, 25th June, 2026, at 2:00 p.m. (IST) via Video Conferencing. - Key agenda items include the adoption of audited financial statements for FY 2025-26 and the declaration of a final dividend of ₹13/- per equity share (650%). - The AGM will also cover the re-appointment of Mr. Adil Zainulbhai as a director, appointment of Statutory Auditors, and ratification of Cost Auditor's remuneration. - The Record Date for the dividend is Friday, 5th June, 2026. Remote e-voting commences on June 21, 2026, and ends on July 24, 2026.

Business Update Neutral

2026-05-28 16:03

Cipla Limited informed about an upcoming in-person meeting with Citi India Conference scheduled for 5th June 2026 in Mumbai. The company noted that the schedule is subject to change due to unforeseen circumstances.

Business Update Positive

2026-05-15 18:35

Cipla management guided for North America to achieve a $1 billion run rate by the end of FY27 and expects strong double-digit growth in its India business for FY27-28. EBITDA margins are projected to be 18.5-20% for FY27, targeting over 20% in FY28, excluding Lanreotide's contribution for FY27. R&D spend will be sustained at 6-7% of revenue, focusing on complex products with 40-50 filings over three years, driving future growth. The company maintains a healthy net cash equivalent balance of INR 10,526 crores and is accelerating AI-led transformation.

Ownership Neutral

2026-05-14 12:12

Cipla Limited announced on May 14, 2026, the allotment of 17,915 fully paid-up equity shares of INR 2 each, following the exercise of employee stock options/stock appreciation rights under its ESOS 2013-A and ESAR 2021 schemes. Consequently, the company's issued, subscribed, and paid-up share capital increased to INR 1,61,56,01,092, comprising 80,78,00,546 equity shares of face value INR 2 each.

Business Update Neutral

2026-05-13 20:06

Cipla Ltd. announced the availability of the audio recording of its earnings conference call for the quarter and financial year ended March 31, 2026, which was held today. The recording is accessible on the company's website at https://www.cipla.com/audio/14837.

Governance Neutral

2026-05-13 13:24

Cipla's Board meeting on May 13, 2026, approved the 90th Annual General Meeting for June 25, 2026. The Board also approved the grant of employee stock options and Employee Stock Appreciation Rights (ESARs). M/s Joshi Apte & Associates was appointed as Cost Auditors for FY 2026-27. Additionally, Mr. Sushrut Kulkarni was appointed as President & Global Chief - Integrated Product Development and Senior Management Personnel, effective May 18, 2026.

Governance Positive

2026-05-13 13:18

Cipla's Board of Directors, at its meeting on May 13, 2026, approved the convening of the 90th Annual General Meeting on June 25, 2026. The board also approved the grant of employee stock options and appreciation rights. Furthermore, M/s Joshi Apte & Associates were appointed as Cost Auditors for FY 2026-27, and Mr Sushrut Kulkarni was appointed as President & Global Chief - Integrated Product Development, effective May 18, 2026.

Governance Positive

2026-05-13 13:14

Cipla's Board of Directors, meeting on May 13, 2026, approved the convening of its 90th Annual General Meeting on June 25, 2026. Key decisions included the grant of employee stock options and ESARs, the appointment of M/s Joshi Apte & Associates as Cost Auditors for FY 2026-27, and the appointment of Mr. Sushrut Kulkarni as President & Global Chief - Integrated Product Development (IPD) and Senior Management Personnel, effective May 18, 2026.

Governance Positive

2026-05-13 13:09

Cipla's Board of Directors, at its meeting on May 13, 2026, approved the convening of the 90th Annual General Meeting on June 25, 2026. The board also approved the grant of employee stock options and appreciation rights (ESARs). M/s Joshi Apte & Associates were appointed as Cost Auditors for FY 2026-27. Additionally, Mr. Sushrut Kulkarni was appointed as President & Global Chief - Integrated Product Development, effective May 18, 2026, strengthening the management team.

CIPLA

Cipla Limited

Price Chart

Filing History

Unlock Full History